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Abstract 
Objectives: To determine the association between the implementation of the 2006 
Australasian Clinical Practice Guidelines for Nutrition in Cystic Fibrosis (CF) and the 
nutritional status of children participating in the Australian Cystic Fibrosis Data Registry 
(ACFDR). 
Methods: This research consisted of a quantitative study using ACFDR data and a survey of 
clinicians and dietitians treating children with CF. Two independent cohorts of children (2-5 
years and 6-11 years) were selected from ACFDR between 1998-2014 (N = 2,304). 
Generalised estimating equation model was used to assess weight, height and body mass 
index (BMI) z-scores for each patient before and after the implementation of the nutrition 
guidelines. A nationwide online survey was sent to 48 clinicians to explore the enablers and 
barriers to implementation of the guidelines. 
Results: Data analysis showed significant increase (p<0.05) in mean weight, height and BMI 
z-scores ranging from 0.06 to 0.18 after implementation of the guidelines in both cohorts of 
children. Nineteen (39%) clinicians participated in the survey. The majority of the 
respondents adopted the recommendations into their practice and used the guidelines as part 
of their professional development. Structural barriers included a lack of adequate staff 
resources and clinic space for consultations, inappropriate staff classification, high staff 
turnover and lack of mentoring support.  
Conclusion: In children participating in the ACFDR, nutritional status improved after the 
implementation of the 2006 guidelines. Survey results revealed enablers and barriers to 
guideline implementation and will inform implementation strategies for the revised 
Australasian nutrition guidelines for CF, released in 2017. 
Keywords: cystic fibrosis, guidelines, nutrition, registry  
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Introduction 
Cystic Fibrosis (CF) is a common, genetically acquired, life-shortening chronic illness 
affecting primarily the lungs and digestive system due to a malfunction in the exocrine 
system, responsible for producing saliva, sweat, tears and mucus [1]. More than 30,000 
people with CF live in the USA and approximately 3,300 in Australia [2, 3]. 
Manifestations of the disease often include frequent respiratory infections resulting in 
progressive scaring of lung tissues and impaired absorption of nutrients resulting in 
suboptimal weight gain and growth [4]. Both malnutrition and poor lung function are 
associated with an increased risk of mortality, therefore, treatments and interventions in 
patients with CF need to aim at maintaining good nutrition and preserving lung function [5-7]. 
Despite recent advances in management of the disease, poor nutrition remains common due 
to increased resting energy expenditure, malabsorption and reduced energy intake [4, 8, 9]. 
Nutritional status and pulmonary function are closely linked and stunting has been found to 
be an independent predictor of mortality in patients with CF [10, 11]. Good nutrition in early 
life is particularly important due to rapid physical and cognitive development. Despite 
improvements, associated with centre-based care, high energy unrestricted fat diets, 
pancreatic enzyme replacement therapy and newborn screening [12-15], the problems of 
growth failure and poor nutritional status remain a challenge [10, 15, 16]. 
In Australia, following a survey of dietetic practice and management of CF in 2006 [6], the 
Dietitian Association of Australia published the 2006 Australasian Clinical Practice 
Guidelines for Nutrition in CF [17]. The guidelines aimed to reduce variations in practice and 
improve the nutritional status and quality of life of patients with CF and their families [6, 17]. 
The guidelines made recommendations regarding dietetic staffing levels, nutritional 
assessment, nutritional requirements, pancreatic enzyme replacement therapy and nutritional 
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support as well as managing complications including pancreatitis and CF related diabetes, 
and special situations including pregnancy and nutrition for lung transplantation. These 
guidelines were distributed to dietitians and other health professionals working in specialist 
CF clinics. They also were published on the websites of professional associations. In addition, 
workshops for dietitians working in specialist CF clinics were held at the Annual Meetings of 
the Dietitians Association of Australia CF Special Interest Group during 2007. 
Recently, evidence-informed and practice based guidelines on the nutritional care of infants, 
children and adults with CF have been established including those by the ESPEN-European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)-ECFS [9], as 
well as the Cystic Fibrosis Foundation (CFF) guidelines on enteral tube feeding both 
published in 2016 [18]. 
To describe trends and patterns of growth and pulmonary function in people with CF, and to 
examine longitudinal associations amongst these variables, a rich data source is needed. To 
collect such information, CF patient registries have been established in the USA, United 
Kingdom, Europe, Australia and New Zealand [19]. The Australian Cystic Fibrosis Data 
Registry (ACFDR) is a national registry that was established in 1998, and collects clinical 
data on patients with CF attending specialist clinics. It captures >90% CF patients enrolled in 
the registry [20, 21], and at the end of 2015 the ACFDR held records of 3,379 Australians 
diagnosed with CF [2]. 
The aim of this study was to determine the association between the implementation of the 
2006 Australasian Clinical Practice Guidelines for Nutrition in CF and the nutritional status 
of children participating in the ACFDR between 1998-2014. 
Material and methods 
Study design 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
5 
 
This quantitative study consisted of two components: 1) analysis of registry data of children 
enrolled in the ACFDR, and 2) survey of clinicians treating children with CF in Australia. 
ACFDR data 
The ACFDR contains detailed demographic and clinical information of patients with a 
confirmed diagnosis of CF, receiving clinical care at twenty-three accredited CF centres in 
Australia (2, 20). Currently there are ten paediatric specialist CF centres participating in the 
ACFDR. On a regular basis, for each patient the registry collects data regarding lung function, 
nutrition, mutation, respiratory microbiology, hospitalisation and treatment. The registry 
provides detailed annual and centre-specific reports, distributed to the clinicians in the 
participating sites. A detailed description of the registry is described elsewhere [2, 21]. 
In this study, nutritional data of children from two independent cohorts, 2-5 and 6-11 years of 
age, were collected longitudinally from 1998 to 2014. We have chosen two different age 
cohorts due to differences in rates of normal growth, eating behaviour and development of 
children between these two groups. This choice was based on the Centres for Disease Control 
and Prevention Growth Charts [22].  
Survey 
A simple ten-question anonymous survey was conducted among medical staff (paediatric 
consultants and fellows in respiratory/thoracic medicine and registrars in an accredited 
respiratory medicine program) and dietitians across Australian paediatric specialist CF 
centres aiming to explore enablers and barriers to the implementation of the 2006 nutrition 
guidelines at their centres. Doctors were identified through their centre’s involvement in the 
ACFDR and dietitians were identified through the Dietitians Association of Australia CF 
Interest Group network. 
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The survey was based on the theoretical domains framework [23] to examine current practice 
and identify enablers and barriers associated with the implementation of the guidelines. The 
survey consisted of the following four components: 1) demographic characteristics of 
participants, 2) implementation of the guidelines, 3) guideline recommendations, and 4) 
evidence for the guidelines. A survey was delivered online via Qualtrics Survey Software [24] 
between August 2017 and February 2018. 
Outcome measures 
Nutritional parameters analysed in this study were weight, height and body mass index (BMI) 
function measurements (z-scores) obtained on the occasion of the best lung function annually. 
Z-scores represent child's or adolescent's weight, height or BMI relative to the distribution of 
weights/heights/BMI observed in a normal reference population of children and adolescents 
of the same sex and age, transformed onto a standardised scale representing the signed 
distances from the population mean divided by the standard deviation. These scores are 
compiled for children and adolescents aged from 2 to less than 18 years using the tables 
published by Centres for Disease Control and Prevention [25]. 
Confounding factors 
Age, sex, pancreatic status, dornase alfa (Pulmozyme) therapy, number of ever-colonised 
positive sample of Pseudomonas aeruginosa and presence of a G551D mutation were 
considered as potential confounders in this study. 
Dornase alfa (Pulmozyme) was included to the analysis as a possible confounder because of 
its mucolytic therapy use, which might be an indication of a more severe lung disease and 
could potentially result in poorer nutritional outcomes in children undertaking this therapy 
[26]. Dornase alfa (Pulmozyme) was listed on the Australian Pharmaceutical Benefits Scheme 
in 1996 and recommended for children age of six years or older [27]. In 2009 the listing was 
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extended to those under five years of age with more severe lung disease. Compared to the 
USA, the lower rate of dornase alfa (Pulmozyme) use in Australia was likely to be due to 
strict qualification criteria for government subsidisation of this expensive medication, which 
in 2003 limited ongoing use to those who had demonstrated an improvement in lung function 
of at least 10% within a month of initiating treatment [28]. 
Another major factor associated with increased morbidity and mortality and, therefore, poorer 
nutritional outcomes in CF patients is chronic Pseudomonas aeruginosa infection [29, 30]. 
Starting from the late 1990s, eradication treatment for Pseudomonas aeruginosa, to prevent 
or delay chronic infection, became more widely adopted [31] with the process formally 
recognised in the 2008 CF Standards of Care in Australia [32]. We accounted for the possible 
influence of improved treatment and medication in our analysis via adjusting for the number 
of ever-positive Pseudomonas aeruginosa results recorded in the registry. 
Recent studies have shown that the use of CF transmembrane conductance regulator (CFTR) 
modulator ivacaftor in responsive gating mutations, improves the nutritional outcomes of CF 
patients [33-35]. Widespread use of ivacaftor in Australia did not occur until 2014 after 
approval by the Therapeutic Goods Association for use in children of six years of age and 
more with G551D mutation (https://www.tga.gov.au/auspar/auspar-ivacaftor). A small 
number of children also had access to the treatment in Phase III clinical trials conducted 
between 2009 and 2011; however, the exact number of patients is not known, as this was not 
recorded in the registry [36, 37]. In 2015, 6.4% of the total CF population had the G551D 
mutation [2]. Despite low numbers of exposure to ivacaftor in the study sample, there is a 
possibility of a substantial change in nutrition amongst those receiving this treatment. Since 
the ACFDR commenced collecting the ivacaftor data in 2016, the gating mutation G551D 
was used as a proxy for exposure to ivacaftor in the analysis. 
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Statistical analyses 
ACFDR data 
Descriptive statistics were used to describe the study population and nutritional outcomes in 
children with CF before and after the implementation of the 2006 guidelines. Generalized 
estimating equations (GEE) models were employed to examine the associations between the 
nutritional status and introduction of the guidelines in 2006. GEE modelling is appropriate for 
analysis of the longitudinal data, as it is used to estimate the parameters of a generalized 
linear model with a possible unknown correlation between outcomes and it could be 
interpreted in a similar way to linear regression [38]. Because the outcomes of the model are 
continuous, a Gaussian distribution for the family of distributions was specified, along with 
an identity link function for the model and the exchangeable correlation matrix. 
Two GEE models, one unadjusted, and another adjusted for age, sex, pancreatic status, use of 
dornase alfa (Pulmozyme), a number of ever-colonised positive Pseudomonas aeruginosa and 
G551D mutation were designed to compare nutritional outcomes in children 2-5 and 6-11 
years of age. Comparisons were made between two periods for each group: 1998-2006 
(before the implementation of the 2006 nutrition guidelines) and 2007-2014 (after the 
implementation of the 2006 nutrition guidelines). 
For all analyses in this study, level of significance was set to 5%. 
Data analysis was conducted in Stata 15.0 (StataCorp, College Stationb, TX, USA). 
Survey data 
All survey responses were anonymous and managed using a simple numerical identifier. 
Descriptive statistics were reported as frequencies in each response category, or means (SD) 
for continuous type of the data that were collected in a Likert scale. 
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Ethics approval 
Collection analysis of the data for this study were approved by the Human Research Ethics 
Committee (RES-17-0000-384L) at Monash Health, Melbourne, Victoria. Institutional ethics 
committee approval was obtained from the participating ACFDR sites providing paediatric 
care and the approaches made to clinicians to participate in the survey. 
Results 
ACFDR data 
The study sample of 2,304 children with CF aged 2-5 and 6-11 in any of the years from 1998 
to 2014 was extracted from the ACFDR. This resulted in a total of 18,261 annual records 
with clinical measurements over the study period in 1998-2014, of which 4,146 (30.8%) and 
3,595 (74.5%) for children 2-5 and 6-11 years of age respectively were recorded prior to the 
implementation of the nutrition guidelines in 2006 (Table1). 
 [Table 1 about here please] 
Of the records obtained from children 2-5 years of age, more than seven percent had one or 
more copies of the G551D mutation, 85.2% of records indicated pancreatic insufficiency, 
25.3% of the records identified the use of dornase alfa, and 35.9% had at least one record of 
positive Pseudomonas aeruginosa. Of the records obtained from children 6-11years of age, 
six percent had one or more copies of the G551D mutation, 78.1% indicated pancreatic 
insufficiency, 36.5% identified the use of dornase alfa and 31.7% had at least one record of 
positive Pseudomonas aeruginosa. In both groups of children, unadjusted values of weight, 
height and BMI z-scores increased after the implementation of the guidelines (Table 1). 
Figure 1 illustrates unadjusted means and 95% confidence intervals (CI) of the longitudinal 
weight, height and BMI z-scores over the period of 1998 to 2014. This means that in any 
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given year, some of the study participants had joined the registry later (e.g. newly diagnosed 
patients in 2007-2014), therefore resulting in the lower initial z-scores of these later entrants. 
 [Figure 1 about here please] 
Figure 1A shows weight z-scores for children 2-5 years of age. Mean [95% CI] weight z-
scores ranged from -0.03 [-0.17-0.11] in 1998 to -0.14 [-0.21-0.06] in 2006. Mean weight z- 
scores were 0.03 [-0.01-0.08] in 2014. In children 6-11 years of age (Figure 1B), mean 
weight z-scores ranged from -0.37 [-0.47-0.26] in 1998 to -0.18 [-0.30-0.05] in 2006 and to -
0.07 [-0.30-0.15] in 2014. Similar trends can be observed in height z-scores and are depicted 
in Figures 1C and 1D. Mean [95% CI] BMI z-scores are shown in Figures 1E and 1F. In 
children 2-5 years of age the mean BMI scores were 0.11 [-0.03-0.24] in 1998 and 0.22 
[0.17-0.28] in 2014 (Figure 1E). In children 6-11 years of age (Figure 1F), mean BMI z-
scores were -0.06 [-0.16-0.03] in 1998 and -0.02 [-0.24-0.21] in 2014.  
Table 2 summarises the results of the unadjusted GEE model analysis of mean changes in 
weight, height and BMI z-scores before and after implementation of the nutrition guidelines 
in 2006. 
[Table 2 about here please] 
For children 2-5 years of age, there was a decrease in weight (mean difference of -0.13, 
95%CI [-0.15, -0.11]), height (mean difference of -0.17, 95%CI [-0.19, -0.15]) and BMI z-
scores (mean difference of -0.13, 95%CI [-0.15-0.10]). In children 6-11 years of age, mean 
weight and height z-scores increased by 0.07, 95% CI [0.04-0.11] and 0.08, 95%CI [0.04-
0.11] respectively. In this group of children, change in BMI z-scores was not statistically 
significant. However, when adjusted for sex, age, pancreatic status, dornase alfa, number of 
ever-colonised positive sample of Pseudomonas aeruginosa and G551D mutation, the model 
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demonstrated a significant increase in weight, height and BMI z-scores in both groups of 
children after the implementation of nutrition guidelines in 2006 (Table 3). 
[Table 3 about here please] 
Survey results 
Nineteen (39%) responses were received from 48 doctors and dietitians invited to the survey. 
Thirteen (68%) of the survey respondents were dietitians and six (32%) were doctors working 
in CF for an average of 6.8 and 21.3 years respectively. Seven (37%) of the respondents 
worked in the field of CF both pre- and post- introduction of the nutritional guidelines, an 
additional three (16%) commenced during the introduction of the guidelines, and the 
remaining nine (47%) commenced after the 2006 guidelines were introduced. On average, the 
respondents spent 18.5 (9.9) hours per week in CF related work (Table 4A). 
[Table 4 about here please] 
Regarding acceptability and use, the guidelines were used by seventeen (89.5%) respondents. 
Fifteen (79%) respondents adopted the recommendations into their practice; 12 (63%) used 
the guidelines as part of their professional development and as a part of the orientation for the 
staff new to CF, 10 (53%) used them to advocate for change to practices and for education of 
clinicians and practitioners, and 8 (42%) used them to advocate for resources. The guidelines 
were understandable and well accepted by the team and patients/carers. Many reasons were 
cited as enablers to implementation, including that they were understandable and accepted by 
the team (47% of respondents cited each of these factors as specific enablers); and that they 
reflected current practices at the time of publication (68% citing this as an enabling factor) 
(Table 4A). 
Regarding barriers to implementation, ten (53%) of the survey participants said there was 
inadequate staff resources, followed by insufficient resources and supporting educational 
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materials from four (21%) respondents, and limited high level evidence available for some 
guideline elements from five respondents (26%). Other structural barriers included lack of 
clinic space for consultations, inappropriate staff classification, high staff turnover and lack 
of mentoring support (Table 4A). 
Respondents’ experiences of applying the guidelines varied between dietitians and doctors. 
Dietitians viewed dietetic staffing levels as the most difficult recommendation to achieve, 
with the mean (SD) rating being 7.2 (3.5), where a rate of zero was considered as easy and 10 
as hard. The next two most difficult recommendations were in relation to nutritional 
assessment for pregnancy and pancreatic enzyme replacement, with mean (SD) ratings of 4.0 
(3.8) and 3.1 (4.1) respectively. Implementation of the other topics was considered easier 
(ratings between 1.9 and 2.8). 
Doctors rated achieving dietetic staffing levels as the most difficult with the mean (SD) score 
of 7.5 (2.9), followed by nutritional assessment and management for pregnancy and lung 
transplantation with the mean (SD) score of 5 (3.1), and the nutrition-related co-morbid 
conditions (e.g. CF related diabetes, gastro-oesophageal reflux disease, distal intestinal 
obstruction syndrome, liver disease, bone health, pancreatitis) as easiest with the mean (SD) 
of 2 (2.8). 
Survey participants were asked to rate the quality of the evidence on the following statements: 
1) the guidelines are more suited to researchers than busy clinicians; 2) they are hard to 
explain to parents and patients; 3) they are too theoretical; 4) they are helpful because the 
categories are like a "traffic light guide", or 5) they are helpful in explaining to patients that 
science is not black and white (Table 4B). The average ratings on these topics were similar 
varied from 2.1 (statement 1) to 3.0 (statement 5) in dietitians, where a rate of zero was 
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considered as easy and 10 as hard. In doctors they varied from 2.0 (statements 1 and 2) to 4.0 
(statement 4) in doctors. 
Discussion 
Optimal nutrition in patients with CF is very important and it is critical in children as it 
impacts growth [4, 39]. Moreover, nutritional status is positively associated with pulmonary 
function and survival [8]. King’s et al [6] research of nutritional management of CF in 
Australia and New Zealand prior to the 2006 guidelines found that although consistent 
nutritional advice was provided by dietitians, there was great variation in the way in which 
energy requirements were calculated and in the criteria used to initiate and cease oral and 
enteral nutrition support. To facilitate optimal outcomes for patients with CF and to promote 
consistency and equity of healthcare and evidence based practice throughout Australia and 
New Zealand, the Australasian Clinical Practice Guidelines for nutrition in CF were released 
in 2006.  
To compare nutrition outcomes before and after the implementation of the guidelines we 
chose two independent groups of children of 2-5 and 6-11 years of age. The older age group 
was much smaller than the younger group. When the registry was established in 1998, a 
contingent of children 6-11 years of age were added to the registry, but these children were in 
most cases diagnosed with CF earlier. Therefore, this contingent was larger than would be 
added in future years. In subsequent years, children would typically join the registry the year 
they were diagnosed or soon thereafter and, therefore, be assigned to the younger cohort. 
The results of our study indicated that nutritional outcomes improved in children participating 
in the ACFDR after the implementation of the guidelines in 2006, suggesting that nutrition 
guidelines made a positive impact and were well accepted amongst clinicians. This finding 
became very much apparent after adjusting the GEE model for sex, age, pancreatic status, 
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dornase alfa (Pulmozyme), number of ever-colonised positive sample of Pseudomonas 
aeruginosa and G551D mutation. Our findings supports the results from the recent US 
studies which also demonstrated improvements in nutritional status in children with CF after 
implementation of quality improvement initiatives based on nutrition practice guidelines [40-
42]. Notwithstanding, given the increasing prevalence of obese children in developed 
countries, it was important to rule out the possibility that improvement in nutritional 
outcomes of children with CF was partially due to changes in eating behaviour of a whole 
generation. A systematic review of 264,905 Australians aged 2–18 years conducted by Olds 
et al [43] demonstrated a plateau, or only slight increase, in the percentage of boys and girls 
classified as overweight or obese, with almost no change in 2000-2010. This suggests that the 
prevalence of overweight and obesity seemed to have flattened over the study period and had 
not followed the anticipated exponential trajectory of increase in weight and BMI in a healthy 
paediatric population.  
Nearly 40% of invited survey participants expressed their views on the nutritional guidelines. 
Overall, they agreed they were useful in change of practice. The majority of respondents 
worked equally with inpatients and outpatients (69%), which indicates that results of the 
survey can be generalised across both the inpatient and outpatient environments.  
Lack of adequate staff resources was most frequently identified as a factor, which made the 
2006 nutrition guidelines difficult to implement. This could potentially indicate that the issue 
of shortfalls in recommended staffing levels [6, 8], observed to be at 0.15 full-time equivalent 
per 50 patients compared to recommended 0.5 full-time equivalent per 50 to 75 patients in the 
CF Australia Standards of Care 2008 [32], have still not fully been addressed. 
Increasing difficulty in application of the guidelines as children age may reflect issues such as 
the difficulty in monitoring eating and medication use at school, and the development of 
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independence, which may impact adherence. The slightly increasing difficulty in application 
of the guidelines in school-aged children and adolescents compared with infants and the 
newly diagnosed patient,  may reflect increasing complexity of care needs including differing 
developmental and environmental barriers to implementation that occur during these age 
groups. Infant care includes supporting breast feeding, monitoring calorific intake and 
introducing Pancreatic Enzyme Replacement Therapy (PERT) at meal times. As children 
grow, common behaviours of food refusal and fussy eating make implementing dietary intake 
guidelines difficult and starting school requires training children to take tablets and the 
education of school staff.  As adolescents become more independent, rejection of CF 
treatments may occur at time when adequate energy is required for growth. These barriers are 
acknowledged and explored in the guidelines. Recommendations of nutrition in pregnancy 
may have been viewed as difficult to implement due the relative rarity of pregnancy in CF 
paediatric care in Australia.  
The respondents judged the categories of evidence for the guidelines for the most part 
positively, as the survey results indicated they were just as suited to clinicians as to 
researchers; and they were easy to explain to parents and patients, and were not too 
theoretical. More neutral survey responses were observed regarding the utility of the 
guidelines as a traffic light system, and the helpfulness of the categories to explain how some 
research is better than others [6, 44]. 
Strengths and limitations 
Registry data is a high quality source of nutritional outcome information for CF patients, and 
is an ideal tool for conducting such analyses and evaluating effectiveness of the nutritional 
strategies and the efforts to obtain optimal growth in CF children, and the importance to 
maintain adequate nutritional status in patients with CF [41]. 
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Our study had a large sample size and number of participants with comprehensive data of 
nutritional outcomes across various groups of patients with CF. All eligible patients on the 
ACFDR were identified through the health records at participating ACFDR sites, thus 
reducing the risk of selection bias. The registry also provides over 90% of the population with 
CF in Australia and has collected diagnostic and outcome data since 1998 with the 
completeness of clinical measurements including pulmonary function and BMI being close to 
100%. 
However, the study does have some limitations. The registry was established in 1998 and 
over the years it has been updated to include new data elements, however not all of the new 
data elements, particularly those related to the confounders, have been completely collected. 
For example, in 2015 microbiology data was reported for only 65% of the registry 
participants [2]. In addition, the registry does not collect data on chronic infection for those 
with Pseudomonas aeruginosa, and the age of acquisition of chronic infection might play an 
important role in determining effects on nutritional status. Furthermore, it is possible that 
there were improvements in symptomatic pulmonary therapy as well as more caretaking in 
specialised CF centres during the period from 1998-2014 that could also influence the 
nutritional status. However, the information on the above-mentioned factors has not been 
collected systematically and, therefore, it could not be considered as a confounding factor in 
the analysis. Finally, the ACFDR uses routinely collected data, with records entered by 
hospital staff, and so we cannot exclude the possibility of data coding and input errors.  
The moderate response rate may reflect factors such as staffing changes. It is also possible 
that some of those who did not respond might have been relatively new to the area, and, 
therefore felt less equipped to answer questions about the introduction of the guidelines some 
year earlier.  
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The results of the survey provide a useful summary of the achievements and limitations of the 
guidelines; however, a small sample of respondents may reflect selection bias and not be 
broadly representative. 
Future directions 
Findings from this study suggest that in children participating in the ACFDR, nutritional 
status improved after the implementation of the 2006 nutrition guidelines. The revised 
Australasian nutrition guidelines for CF were released in late 2017 [45]; therefore, there is an 
opportunity to use the findings from this research to identify enablers and barriers to 
guideline implementation and inform implementation strategies for the updated guidelines 
and for other clinical practice guidelines for CF. Ongoing analysis of nutritional outcomes 
using periodic data from the ACFDR, and continual identification of emerging potential 
confounders to consider in such analyses, will be essential to evaluate the success of these 
and other significant nutritional initiatives that aim to improve the care and outcomes for 
individuals with CF and their families into the future. 
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Tables 
Table 1. Demographic characteristics of the study participants at the year they joined the 
ACFDR (N = 2,304) diagnosed with CF in 1998-2014. 
Characteristics 2 - 5 years of age 6 - 11 years of age 
 
Patients, N (%) 1,655 (71.8) 649 (28.7) 
Sex   
Male, N (%) 836 (50.5) 331 (51.0) 
Female, N (%) 819 (49.5) 318 (49.0) 
G551D mutation, N (%) 120 (7.3) 39 (6.1) 
Records with clinical 
measurements 1998-2014, N (%) 
13,437 (73.6) 4,824 (26.4) 
Records with clinical 
measurements prior to the 
intervention*, N (%) 
4,146 (30.8) 3,595 (74.5) 
Records indicating Dornase alfa 
use 1998-2014, N (%) 
3,382 (25.3) 1,745 (36.5) 
Records indicating pancreatic 
insufficiency, 1998-2014, N (%) 
11,315 (85.2) 3,698 (78.1) 
Records with positively populated 
Pseudomonas aeruginosa 1998-
2014, N (%) 
  
One 2,061 (35.9) 1,079 (31.7) 
Two 795 (13.9) 682 (20.0) 
Three 45 (0.8) 107 (3.1) 
Four 93 (1.6) 6 (0.2) 
Weight z-score prior to the 
intervention*, mean [95% CI] 
-0.09 [-0.13; -0.07] -0.35 [-0.38; -0.31] 
Weight z-score post- 
intervention*, mean [95% CI] 
0.01 [-0.01; 0.03] -0.11 [-0.17; -0.06] 
Height z-score prior to the 
intervention*, mean [95% CI] 
-0.22 [-0.25; -0.19] -0.46 [-0.49; -0.43] 
Height z-score post- 
intervention*, mean [95% CI] 
-0.23 [-0.25; -0.21] -0.23 [-0.30; -0.18] 
BMI z-score prior to the 
intervention*, mean [95% I] 
0.12 [0.09; 0.15] -0.11 [-0.14; -0.08] 
BMI z-score post- intervention*, 
mean [95% CI] 
0.24 [0.22; 0.25] 0.02 [-0.03; 0.07] 
Note: *implementation of the nutrition guidelines in 2006 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
26 
 
Table 2. Mean changes in weight, height and body mass index (BMI) z-scores before and 
after the implementation of the 2006 nutrition guidelines (unadjusted analysis) 
Outcome 2-5 years of age   6-11 years of age   
  Mean 
difference* 
95% CI p-value Mean 
difference* 
95% CI p-value 
Weight z-score -0.13  -0.15 -0.11 <0.001 0.07  0.04 0.11 <0.001 
 
        
Height z-score -0.17  -0.19 -0.15 <0.001 0.08 0.04 0.11 <0.001 
         
BMI z-score -0.13 -0.15 -0.11 <0.001 -0.02 -0.06 0.02 0.423 
Note: * reference group is pre-intervention (i.e. before the implementation of the nutrition 
guidelines in 2006). All p-values from generalised estimating equation models correctly accounting 
for within patient correlation using the exchangeable correlation matrix.  
 
Table 3. Mean changes in weight, height and body mass index (BMI) z-scores before and 
after the implementation of the 2006 nutrition guidelines (adjusted analysis) 
Outcome 2-5 years of age   6-11 years of age   
  Mean 
difference* 
95% CI p-value Mean 
difference* 
95% CI p-value 
Weight z-score 0.14 0.08 0.20 <0.001 0.11  0.04 0.18 0.001 
 
        
Height z-score 0.04 -0.01 0.09 0.109 0.11 0.05 0.17 <0.001 
         
BMI z-score 0.18  0.12 0.24 <0.001 0.08 0.01 0.17 0.029 
Note: * reference group is pre-intervention (i.e. before the implementation of the nutrition 
guidelines in 2006). All p-values from generalised estimating equation models correctly accounting 
for within patient correlation using the exchangeable correlation matrix. Estimates adjusted for sex, 
age, pancreatic status, use of dornase alfa (Pulmozyme), number of positive Pseudomonas 
aeruginosa and G551D mutation. Age represents age at the first presentation to the registry. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
27 
 
Table 4. Summary of the dietitians and doctors survey responses. Table 4A summarises 
responses to categorical survey questions, shown as n (%). Table 4B provides responses to 
survey rating questions, presented as mean (SD). 
Table 4A 
Survey questions Dietitians  
(n = 13) 
Doctors  
(n = 6) 
Overall 
 (n = 19) 
Mean (SD) time in working in CF, years  6.8 (4.8) 21.3 (11.3) 11.4 (9.9) 
Type of patients seen, n (%)    
Inpatients 1 (7.7) 0 (0) 1 (5.3) 
Outpatients 3 (23.1) 2 (33.3) 5 (26.3) 
Both 9 (69.2) 4 (66.7) 13 (68.4) 
Mean (SD) time spent on CF work per week, hours 19.9 (8.2) 15.3 (13.2) 18.5 (9.9) 
Used the guidelines, n (%) 13 (100) 4 (66.7) 17 (89.5) 
Ways of how the guidelines were used, n (%)*    
Adopted into practice for assessments 12 (93.3) 3 (50) 15 (78.9) 
As part of orientation for those new to CF 9 (69.2) 3 (50) 12 (63.2) 
As professional self-development 9 (69.2) 3 (50) 12 (63.2) 
For education of clinicians/practitioners 8 (61.5) 2 (33.3) 10 (52.6) 
To advocate for resources 7 (53.8) 1 (16.7) 8 (42.1) 
To advocate for change to practices 9 (69.2) 1 (16.7) 10 (52.6) 
Enablers that helped to implement the guidelines, 
n (%)*  
   
Reflected current practice 10 (76.9) 3 (50) 13 (68.4) 
A simple change was required 3 (23.1) 3 (50) 6 (31.6) 
Not costly 3 (23.1) 2 (33.3) 5 (26.3) 
Well accepted (by team/patients/carers) 7 (53.8) 2 (33.3) 9 (47.4) 
Understandable 7 (53.8) 2 (33.3) 9 (47.4) 
Factors that made the guidelines hard to 
implement, n (%)* 
   
No or limited high level evidence available for some 
topics 
4 (30.8) 1 (16.7) 5 (26.3) 
Lack of adequate staff resources 8 (61.5) 2 (33.3) 10 (52.6) 
Insufficient funding for products 3 (23.1) 1 (16.7) 4 (21.1) 
Lack of educational material 3 (23.1) 1 (16.7) 4 (21.1) 
Not accepted by CF team members 1 (7.7) 0 1 (5.3) 
Other structural barriers for implementation, n 
(%)* 
   
High staff turnover 1 (7.7) 1 (16.7) 2 (10.5) 
Inappropriate staff grading/classification 3 (23.1) 0 (0) 3 (15.8) 
Lack of clinic space for consultations 5 (38.5) 1 (16.7) 6 (31.6) 
Lack of mentoring support 2 (15.4) 0 (0) 2 (10.5) 
*Multiple responses allowed per question, therefore numbers add to more than 100% 
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Table 4B 
Survey questions Dietitians  
(n = 13) 
Doctors  
(n = 6) 
Overall 
 (n = 19) 
Guideline recommendation topics, mean (SD)#    
Dietetic staffing levels 7.2 (3.5) 7.5 (2.9) 7.3 (3.3) 
Nutritional assessment 1.9 (1.2) 5 (3.6) 2.7 (2.4) 
Nutritional requirements for macronutrients, 
vitamins and mineral 
2.7 (1.4) 4.3 (2.9) 3.1 (1.9) 
Pancreatic enzyme replacements 2.3 (1.4) 4.3 (3.6) 2.8 (2.2) 
Nutritional assessment for pregnancy 4 (3.8) 5 (-) 4.1 (3.6) 
Nutritional management for lung transplantation 2.6 (3.8) 5 (3.1) 3.1 (3.3) 
Blood testing 2.8 (1.4) 2.5 (4.4) 2.7 (2.3) 
Other tests (e.g. gastroenterological test, pancreatic 
function tests) 
2.8 (1.7) 5.3 (3.8) 3.4 (2.5) 
Routine nutritional interventions 2.5 (2.1) 4 (3.9) 2.9 (2.6) 
Nutrition-related co-morbid conditions (e.g. CF 
related diabetes, GOR, DIOS, liver disease, bone 
health, pancreatitis) 
2.8 (0.9) 2 (2.8) 2.6 (1.6) 
Infants and newly diagnosed patients 1.9 (1.2) 3.5 (3.7) 2.3 (2.1) 
Young children 2.4 (1.4) 4 (3.2) 2.8 (2.0) 
Adolescents 2.7 (1.8) 4.3 (2.9) 3.1 (2.2) 
Guideline evidence categories, mean (SD) #    
More suited to researchers than busy clinicians 2.1 (1.5) 2 (1.8) 2.0 (1.5) 
Hard to explain to parents/patients 2.3 (1.8) 2 (1.8) 2.2 (1.6) 
Too theoretical 2.4 (1.3) 2.5 (0.6) 2.4 (1.1) 
Helpful because of a ‘traffic like guide’ 2.8 (1.1) 4 (0.8) 3.1 (1.1) 
Helpful in explaining to patients that science is not 
black and white  
3.0 (1.3) 3.8 (0.9) 3.2 (1.3) 
#Participants were asked to rate topic areas on a scale from 0 (easy) to 10 (hard) 
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Figures 
Figure 1. Unadjusted weight, height and BMI z-scores before and after the release of the 2006 nutrition guidelines (shown as a dashed line). 
Figure A and B show mean and 95% confidence intervals (CI) weight z-scores for children of 2-5 and 6-11 years of age respectively. Figure C 
and D show mean and 95% CI height z-scores for children of 2-5 and 6-11 years of age. Figure E and F show mean and 95% CI BMI z-scores 
for children of 2-5 and 6-11 years of age.  The mean values and the 95% confidence intervals are unadjusted. 
 
